ArticleJournal of virology2025
The role of chikungunya virus capsid-viral RNA interactions in programmed ribosomal frameshifting.
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Chikungunya virus (CHIKV) is a globally significant arthropod-borne virus that causes outbreaks in tropical and subtropical regions and is rapidly expanding in geographical range. Infection can lead to acute febrile illness with debilitating joint pain that may persist as chronic arthritis. Efficient CHIKV replication and virion assembly rely on coordinated interactions between viral RNA and the capsid protein, a structural component essential for particle formation. In addition to its well-established structural role, the alphavirus capsid protein has been shown in Sindbis virus to bind viral RNA and stabilize the genome, while in New World alphaviruses, it contributes to immune evasion through inhibition of host gene expression. However, its potential regulatory functions in viral RNA processes remain less understood. Here, we show that CHIKV capsid modulates programmed ribosomal frameshifting (PRF) within the 6K/Transframe (TF) region, influencing the balance between structural protein synthesis and TF production. Using a previously engineered CHIKV mutant (9900), which contains silent mutations that reduce capsid binding within 6K/TF, we demonstrate that diminished capsid-vRNA interaction correlates with increased PRF efficiency. This is associated with enhanced viral replication in immune-competent cells, yet this enhanced replication is not further improved by JAK-STAT inhibition, indicating that capsid binding already modulates immune response pathways. These findings identify CHIKV capsid as a potential modulator of PRF, expanding our understanding of alphavirus gene expression and RNA-protein interactions. IMPORTANCE: The multifunctional roles of the chikungunya virus (CHIKV) capsid protein-particularly its RNA-binding properties and potential to influence translation-represent important aspects of viral replication and pathogenesis. This study focuses on the CHIKV capsid's influence on PRF, a key step in viral protein synthesis. Similar capsid-vRNA binding regions have been described in other alphaviruses, such as Venezuelan equine encephalitis virus (B. D. Carey, I. Akhrymuk, B. Dahal, C. L. Pinkham, et al., PLOS Pathogens 16:e1008282, 2020, https://doi.org/10.1371/journal.ppat.1008282), suggesting that capsid-mediated modulation of translation may represent a partially conserved mechanism across the alphavirus genus. By elucidating a role for capsid in PRF modulation, this study highlights a previously unrecognized layer of gene regulation in alphaviruses with broad implications for immune evasion, viral fitness, and translational control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.